Standard BioTools Inc. (LAB) Operating Margin
- Operating margin · 12 months: Value -112.85%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -112.85% | Operating income / revenue. Period ending 2026-06-30. $-95.47M ÷ $84.60M × 100 ≈ -112.85% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -95.47M USD | Operating Income (Loss) |
| Revenue | 84.60M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 41.89M USD | Cost of Goods and Services Sold |
| Research and development | 18.42M USD | Research and Development Expense |
| Selling, general and administration | 86.93M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-95.47M | $84.60M | $41.89M | $18.42M | $86.93M | -112.85% |
| 2026-03-31 | $-95.78M | $86.25M | $43.45M | $22.66M | $98.64M | -111.04% |
| 2025-12-31 | $-110.25M | $85.33M | $42.79M | $25.99M | $109.86M | -129.20% |
| 2025-09-30 | $-159.44M | $169.74M | $87.84M | $58.64M | $165.39M | -93.93% |
| 2025-06-30 | $-153.20M | $172.27M | $87.73M | $59.22M | $163.26M | -88.93% |
| 2025-03-31 | $-148.02M | $169.69M | $89.87M | $57.76M | $148.37M | -87.23% |
| 2024-12-31 | $-175.24M | $174.43M | $90.17M | $62.41M | $156.61M | -100.46% |
| 2024-09-30 | $-163.81M | $155.90M | $80.19M | $55.27M | $140.37M | -105.07% |
| 2024-06-30 | $-153.26M | $136.30M | $72.64M | $48.54M | $128.26M | -112.44% |
| 2024-03-31 | $-120.19M | $126.76M | $64.40M | $35.50M | $113.19M | -94.82% |
| 2023-12-31 | $-76.60M | $106.34M | $55.89M | $25.95M | $87.54M | -72.03% |
| 2023-09-30 | $-76.33M | $105.17M | (m) | $27.58M | $98.88M | -72.57% |
| 2023-06-30 | $-84.18M | $105.45M | (m) | $29.70M | $99.08M | -79.83% |
| 2023-03-31 | $-105.30M | $96.56M | (m) | $36.04M | $106.19M | -109.04% |
| 2022-12-31 | $-116.20M | $97.95M | (m) | $38.50M | $114.76M | -118.64% |
| 2022-09-30 | $-106.35M | $109.19M | (m) | $38.66M | $113.82M | -97.40% |
| 2022-06-30 | $-96.94M | $112.05M | (m) | $39.22M | $108.29M | -86.51% |
| 2022-03-31 | $-75.64M | $124.29M | (m) | $36.06M | $102.16M | -60.86% |
| 2021-12-31 | $-67.46M | $130.58M | (m) | $37.94M | $98.89M | -51.66% |
| 2021-09-30 | $-73.10M | $136.92M | (m) | $40.59M | $107.86M | -53.39% |
| 2021-06-30 | $-58.96M | $148.28M | (m) | $39.51M | $106.45M | -39.76% |
| 2021-03-31 | $-55.41M | $143.32M | (m) | $38.52M | $102.81M | -38.66% |
| 2020-12-31 | $-51.04M | $138.14M | (m) | $36.46M | $97.90M | -36.94% |
| 2020-09-30 | $-43.31M | $125.98M | (m) | $33.55M | $84.76M | -34.38% |
| 2020-06-30 | $-51.66M | $112.61M | (m) | $32.55M | $82.83M | -45.88% |
| 2020-03-31 | $-52.58M | $114.75M | (m) | $31.97M | $84.35M | -45.82% |
| 2019-12-31 | $-51.84M | $117.24M | $52.96M | $31.64M | $84.48M | -44.22% |
| 2019-09-30 | $-53.78M | $117.13M | $51.93M | $31.32M | $87.66M | -45.91% |
| 2019-06-30 | $-51.59M | $119.59M | $52.61M | $31.63M | $86.95M | -43.14% |
| 2019-03-31 | $-49.74M | $117.83M | $52.62M | $31.15M | $83.80M | -42.21% |
| 2018-12-31 | $-48.16M | $112.96M | $51.31M | $30.03M | $79.78M | -42.64% |
| 2018-09-30 | $-45.78M | $108.38M | (m) | $29.23M | $73.67M | -42.24% |
| 2018-06-30 | $-49.75M | $104.17M | (m) | $29.48M | $73.76M | -47.76% |
| 2018-03-31 | $-53.46M | $101.65M | (m) | $29.56M | $75.75M | -52.59% |
| 2017-12-31 | $-58.36M | $101.94M | (m) | $30.83M | $79.52M | -57.25% |
| 2017-09-30 | $-67.32M | $99.28M | (m) | $32.44M | $86.42M | -67.81% |
| 2017-06-30 | $-70.20M | $96.72M | (m) | $34.01M | $87.44M | -72.58% |
| 2017-03-31 | $-71.86M | $100.98M | (m) | $36.53M | $90.31M | -71.16% |
| 2016-12-31 | $-73.19M | $104.45M | (m) | $38.41M | $93.21M | -70.07% |
| 2016-09-30 | $-69.19M | $110.08M | (m) | $39.38M | $92.53M | -62.85% |
| 2016-06-30 | $-58.51M | $116.54M | (m) | $39.57M | $90.96M | -50.20% |
| 2016-03-31 | $-55.02M | $116.99M | (m) | $39.69M | $88.34M | -47.03% |
| 2015-12-31 | $-50.16M | $114.71M | (m) | $39.26M | $82.96M | -43.72% |
| 2015-09-30 | $-46.30M | $117.48M | (m) | $41.24M | $79.71M | -39.41% |
| 2015-06-30 | $-51.54M | $118.47M | (m) | $44.48M | $78.73M | -43.50% |
| 2015-03-31 | $-49.26M | $117.46M | (m) | $45.77M | $76.16M | -41.94% |
| 2014-12-31 | $-51.84M | $116.46M | (m) | $43.42M | $71.32M | -44.51% |
| 2014-09-30 | $-46.65M | $103.85M | (m) | $37.46M | $66.06M | -44.92% |
| 2014-06-30 | $-38.55M | $92.50M | (m) | $29.78M | $59.58M | -41.68% |
| 2014-03-31 | $-30.16M | $82.37M | (m) | $23.40M | $52.52M | -36.62% |
| 2013-12-31 | $-18.65M | $71.18M | (m) | $19.95M | $48.41M | -26.20% |
| 2013-09-30 | $-17.50M | $65.96M | (m) | $18.46M | $45.39M | -26.53% |
| 2013-06-30 | $-16.46M | $60.46M | (m) | $17.53M | $42.40M | -27.22% |
| 2013-03-31 | $-16.86M | $55.92M | (m) | $16.52M | $40.22M | -30.14% |
| 2012-12-31 | $-18.07M | $52.33M | (m) | $16.60M | $38.48M | -34.53% |
| 2012-09-30 | $-17.56M | $49.67M | (m) | $16.34M | $35.89M | -35.35% |
| 2012-06-30 | $-17.70M | $47.48M | (m) | $15.56M | $34.84M | -37.28% |
| 2012-03-31 | $-19.97M | $45.11M | (m) | $14.99M | $33.27M | -44.27% |
| 2011-12-31 | $-18.57M | $42.87M | (m) | $13.94M | $31.30M | -43.31% |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-14.57M | $33.56M | (m) | $13.01M | $23.55M | -43.42% |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $-18.04M | $25.41M | (m) | $12.31M | $19.65M | -70.98% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |